Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CLNN
Clene Inc. (CLNN) Beneish M-score
Clene Inc.'s Beneish M-score for fiscal 2025 cannot be worked out: days’ sales in receivables index cannot be worked out.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2024 | −6.10 | (1.83) |
| FY2023 | −4.26 | (6.92) |
| FY2022 | 2.66 | 0.62 |
| FY2021 | 2.04 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | 1.01 | — | 0.53 | |
| Asset quality index | 1.28 | — | 0.52 | |
| Sales growth index | 0.58 | — | 0.52 | |
| Depreciation index | 0.91 | — | 0.10 | |
| SG&A index | 1.19 | — | −0.20 | |
| Total accruals to total assets | (0.42) | — | −1.97 | |
| Leverage index | 1.43 | — | −0.47 | |
| Beneish M-score | n/a — days’ sales in receivables index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| INMB INmune Bio, Inc. compare | −3.7× |
| IBIO iBio, Inc. compare | 33.5× |
| ACET Adicet Bio, Inc. compare | — |
| KLRS Kalaris Therapeutics Inc. compare | — |
| ELTX Elicio Therapeutics, Inc. compare | — |
| HOWL Werewolf Therapeutics, Inc. compare | — |
| CLNN Clene Inc. | — |
| IMA ImageneBio, Inc. compare | — |
| TVGN Tevogen Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI